Biogaia writes off allergy study

By Stephen Daniells

- Last updated on GMT

Related tags Lactobacillus

Disappointing results from a two-year investigation into the
effects of probiotics on allergies have forced Sweden's Biogaia to
end the research.

The firm said yesterday that it has decided to write-off capitalized development expenditures relating to the research.

Peter Rothschild, managing director of Biogaia, told that is was more prudent to write off the expenses than to continue with an unrewarding study.

The results will disappoint others in the industry who had believed in the ability of probiotic bacteria to help prevent allergies like eczema and asthma if taken from birth.

BioGaia's clinical study was launched in 2001, with 232 newborn infants being given Biogaia's patented Reuteri bacteria. The incidence of eczema, which is the main allergy for young infants, did not decrease with the probiotic supplement.

"It is of course a disappointment that the study did not show the results we expected,"​ said Rothschild.

However he drew some positives from the study, pointing out that there was reduced wheezing among two-year-old infants. Hay fever and asthma are uncommon in early life and this, says Rothschild, shows "clear tendencies that should be examined in future studies."

"We are optimistic that a possible follow-up of the study at a later stage will show reduced incidences of asthma and hay fever,"​ he added.

The results come just as the small firm approaches profitability. It has written off SEK 10.8 million (€1.15m) in development expenses, and SEK 4.9 million (€0.5m) to reverse provisions for future commitments to pay royalties on future sales of allergy products. Cash flow will not be affected however.

BioGaia said in a statement that it still had a "strong portfolio of innovative products, successful clinical trials and a growing distribution network covering a large share of the key markets"​.

Known as Reuteri, the lactic acid bacterium Lactobacillus reuteri​ has previously been shown to improve gastrointestinal, immune and oral health.

Related news

Show more

Related products

show more

Latest Research Findings on Omega-3s for Heart Health

Latest Research Findings on Omega-3s for Heart Health

Content provided by GC Rieber VivoMega™ | 12-Feb-2024 | White Paper

According to Grandview Research, the global omega-3 market is a $2.62 billion market and is one of the fastest-growing segments in the dietary supplement...

Kaneka Ubiquinol® and Preconception Health

Kaneka Ubiquinol® and Preconception Health

Content provided by Kaneka Nutrients – Manufacturer and Supplier of Kaneka Ubiquinol® | 02-Feb-2024 | White Paper

An ally in the fight against oxidative stress, Kaneka Ubiquinol® offers antioxidant support for men and women concerned about reproductive health.

Related suppliers

Follow us


View more